Healthcare
ByAI Is Reshaping Pharma’s Economics—But Discovery Isn’t the Immediate Win
Executive Summary Artificial intelligence has moved from experimental promise to operational backbone across global biopharma. Industry leaders including…
Can Takeda’s $1.7 Billion Iambic Deal Redefine AI-Driven Small-Molecule Drug Discovery?
Executive Summary In a landmark AI-biopharma transaction, Takeda Pharmaceutical Co Ltd has entered a multi-year collaboration valued at…
Pfizer Repositions for Sustainable Growth in 2025 as Core Therapeutic Franchises Reassert Leadership
Pfizer Inc. reported full-year 2025 revenues of $62.6 billion, marking a pivotal year in the company’s post-pandemic transformation.…
Eli Lilly Delivers Transformational Growth in 2025, Anchored by Metabolic Leadership and Innovation Execution
Indianapolis, IN – February 2026 – Eli Lilly and Company reported exceptional full-year financial and operational performance in…
RecovryAI’s FDA Breakthrough: Post-Op AI Agents’ 85% Complication Prediction or Wearable Hype Meets Reality?
RecovryAI snared FDA Breakthrough Device Designation on March 4, 2026, for its physician-prescribed Virtual Care Assistants—AI agents that…
Ardent Health’s Hellocare.ai Virtual Nursing Play: 20% Readmission Slash or AI Overreach in Care?
Ardent Health’s March 3-4, 2026, partnership with Hellocare.ai deploys AI modules for virtual nursing, telehealth, and real-time patient…
